A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.
复制标题
丙戊酸的II期研究,用于治疗低度神经内分泌癌。
DOI:
10.1634/theoncologist.2011-0031
复制
发表时间:
2011
期刊:
影响因子:
--
通讯作者:
Loconte NK
中科院分区:
文献类型:
--
作者:
Mohammed TA;Holen KD;Jaskula-Sztul R;Mulkerin D;Lubner SJ;Schelman WR;Eickhoff J;Chen H;Loconte NK
Notch1 has been shown to be a tumor suppressor in neuroendocrine tumors (NETs). Previous in-vitro studies in NET cell lines have also suggested that valproic acid (VPA), a histone deacetylase inhibitor, can induce Notch1, and that Notch1 activation correlates with a decrease in tumor markers for NET. Thus, this study aimed to evaluate the role of valproic acid in treating NETs and if VPA induced the Notch signaling pathway signaling in-vivo‥ Eight patients with low grade NETs (carcinoid and pancreatic) were treated with valproic acid 500 mg orally twice a day with dosing adjusted to maintain a goal VPA level between 50–100 mcg/mL. All patients were followed for 12 months or until disease progression. Notch1 signaling was absent in all tumors prior to treatment, and was upregulated with VPA. One patient had an unconfirmed PR and was noted to have a 40-fold increase in Notch1 mRNA levels. Four patients had stable disease as best response. Tumor markers improved in 5/7 patients. Overall, treatment with VPA was well tolerated. Valproic acid activates Notch1 signaling in-vivo and may have a role in treating low grade NET.
登录
查看更多内容
影响因子:
5.8
作者:
Kunnimalaiyaan, Muthusamy;Chen, Herbert
通讯作者:
Chen, Herbert
影响因子:
158.5
作者:
MOERTEL, CG;LEFKOPOULO, M;KLAASSEN, D
通讯作者:
KLAASSEN, D
影响因子:
6.2
作者:
Modlin, IM;Lye, KD;Kidd, M
通讯作者:
Kidd, M
影响因子:
9.8
作者:
Massironi, Sara;Conte, Dario;Peracchi, Maddalena
通讯作者:
Peracchi, Maddalena
DOI:
10.1097/01.coc.0000054535.19808.f4
发表时间:
2004-06-01
影响因子:
2.6
作者:
Ansell, SM;Mahoney, MR;Rubin, J
通讯作者:
Rubin, J